HEALTH
First-of-its-kind annual HIV shot moves closer to reality, passes key trial – Interesting Engineering
- First-of-its-kind annual HIV shot moves closer to reality, passes key trial Interesting Engineering
- Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment aidsmap
- A once-yearly PrEP? Gilead’s lenacapavir shows promise as company plots phase 3 FiercePharma
- Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug Endpoints News
- Reformulation of HIV prevention drug lenacapavir makes it last for a year Medical Xpress
Source link
